

1 **RESEARCH NOTE**

2 **Evolution of SARS-CoV-2 immune responses in nursing home residents following**
3 **full dose of the Comirnaty® COVID-19 vaccine**

4 Estela Giménez^{1†}, Juan Alberola^{2†}, Ignacio Torres¹, Eliseo Albert¹, María Jesús
5 Alcaraz¹, Pilar Botija³, Paula Amat⁴, María José Remigia⁴, María José Beltrán⁵, Celia
6 Rodado⁶, Dixie Huntley¹, Beatriz Olea¹, and David Navarro^{1,2*}

7 ¹*Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute,*
8 *Valencia, Spain.*

9 ²*Department of Microbiology, School of Medicine, University of Valencia, Valencia,*
10 *Spain*

11 ³*Dirección de Atención Primaria, Departamento de Salud Clínico-Malvarrosa,*
12 *Hospital Clínico Universitario de Valencia, Valencia, Spain.*

13 ⁴*Hematology Service Clinic University Hospital, INCLIVA Health Research Institute,*
14 *Valencia, Spain.*

15 ⁵*Dirección de Enfermería, Departamento de Salud Clínico-Malvarrosa, Hospital*
16 *Clínico Universitario de Valencia, Valencia, Spain.*

17 ⁶*Comisión Departamental de control de Residencias. Departamento de Salud València*
18 *Clínico Malvarrosa.*

19 †Both authors contributed equally to the present work.

20

21 ***Correspondence:** David Navarro, Microbiology Service, Hospital Clínico
22 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
23 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010

24 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; E-mail:
25 david.navarro@uv.es.

26 **Running title:** Immunogenicity of Comirnaty® COVID-19 vaccine in nursing home
27 residents.

28 **ABSTRACT**

29 **Objectives:** There is scarce information as to the durability of immune responses
30 elicited by the Comirnaty® COVID-19 vaccine in nursing home residents. Here, we
31 assessed SARS-CoV-2-Spike (S)-targeted antibody and functional T cell responses at
32 around 6 months after complete vaccination.

33 **Methods:** The sample comprised 46 residents (34 females; age, 60-100 years), of whom
34 10 had COVID-19 prior to vaccination. Baseline (median of 17.5 days after vaccination)
35 and follow-up (median, 195 days) plasma specimens were available for quantitation of
36 SARS-CoV-2-S antibodies and enumeration of SARS-CoV-2-S-reactive IFN- γ CD4⁺
37 and CD8⁺ T cells by flow cytometry.

38 **Results:** In total, 44/45 participants had detectable SARS-CoV-2-S antibodies at
39 follow-up. Overall, antibody levels were found to decrease (median, 4.8 fold).
40 Antibodies waning was more frequent ($P<0.001$) in SARS-CoV-2 naïve (29/35) than in
41 recovered (1/10) residents. SARS-CoV-2-S IFN- γ CD8⁺ T cells were detected in 33/46
42 and 24/46 at baseline and follow-up, respectively. The figures for CD4⁺ T cell
43 counterparts were 12/46 and 30/46. Detectable SARS-CoV-2 IFN- γ CD8⁺ and CD4⁺ T
44 cell responses at follow-up were more common in recovered (8/10 and 7/10,
45 respectively) than in naïve residents (9/36 and 25/36, respectively). For those with
46 detectable responses at both time points, SARS-CoV-2-S IFN- γ CD8⁺ T cell frequencies

47 decreased significantly ($P=0.001$) over time whereas the opposite ($P=0.01$) was
48 observed in CD4⁺ T cells.

49 **Conclusion:** Almost all residents displayed detectable SARS-CoV-2-S-reactive
50 antibodies and T cell responses, respectively, by around 6 months after complete
51 vaccination with Comirnaty® COVID-19 vaccine, albeit generally waning in magnitude
52 over time.

53 **Keywords:** SARS-CoV-2, Comirnaty® COVID-19 vaccine, SARS-CoV-2-S
54 antibodies; SARS-CoV-2-S T cells, Nursing home residents.

55 INTRODUCTION

56 Real-world experience has shown mRNA COVID-19 vaccines to be effective in
57 reducing incidence of both asymptomatic and symptomatic SARS-CoV-2 infections and
58 related deaths in nursing home residents [1], congruent with their ability to elicit robust
59 virus-specific T and B cell immune responses in this population group [2-4].
60 Nevertheless, maintaining seemingly protective immune responses in these individuals
61 over time may be compromised by the concurrence of older age, frailty and co-
62 morbidities. To shed light on this issue, here we assessed SARS-CoV-2-Spike (S)-
63 targeted antibody and functional T cell responses at around 6 months after vaccination
64 with Comirnaty® (Pfizer–BioNTech) in a previously recruited cohort [2].

65 MATERIAL AND METHODS

66 Participants and study design

67 Out of 53 nursing home residents enrolled in a previous study [2] with data on B and T
68 cell immunity at a median of 17.5 days (range, 14–35 days) after second vaccine dose
69 (baseline sample), 46 (44 females; median age, 89 years; range, 60–100; Supplementary

70 Table 1) were reassessed (follow-up sample) at a median of 195 days (range, 179–195
71 days). The remaining 7 patients either died (n=4; in no case attributable to COVID-19)
72 or lacked the follow-up specimen (n=3). Blood specimens were collected in sodium
73 heparin tubes (Beckton Dickinson, U.K. Ltd., UK). Informed consent was obtained
74 from participants. The study was approved by the Hospital Clínico Universitario
75 INCLIVA Research Ethics Committee (February, 2021).

76 **Immunological assays**

77 Total antibodies (IgG and IgM) against SARS-CoV-2-S protein receptor binding
78 domain (RBD) and the nucleoprotein (N) were measured by Roche Elecsys®
79 electrochemiluminescence sandwich immunoassays (Roche Diagnostics, Pleasanton,
80 CA, USA). Cryopreserved plasma (-20 °C) specimens were thawed and assayed in
81 singlets within 15 days after collection. Plasma specimens were diluted (1/10) for
82 antibody quantitation when appropriate. SARS-CoV-2-S-reactive
83 IFN γ -producing CD8⁺ and CD4⁺ T cells were enumerated in whole blood by flow
84 cytometry for ICS (BD Fastimmune, BD-Beckton Dickinson and
85 Company-Biosciences, San Jose, CA) as previously described [2].

86 **Statistical methods**

87 Differences between medians were compared using the Mann–Whitney U-test or
88 Wilcoxon test for unpaired and paired data, when appropriate. The Spearman rank test
89 was used for correlation analyses between continuous variables. Two-sided exact *P*-
90 values were reported. A *P*-value <0.05 was considered statistically significant. The
91 analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL, USA).

92 **RESULTS**

93 **SARS-CoV-2 infectious status of participants**

94 Of the 46 residents, 10 (21.7%) had evidence of SARS-CoV-2 infection at baseline, as
95 determined by both RT-PCR on nasopharyngeal specimens and detection of N-specific
96 antibodies. No additional residents developed N-specific antibodies between sampling
97 times.

98 **SARS-CoV-2-S-specific antibodies**

99 Data on SARS-CoV-2-RBD antibody levels were available for 45 participants. All 43
100 residents who tested positive at baseline also displayed detectable responses at follow-
101 up, although overall, antibody levels were found to decrease significantly, by a median
102 of 4.8 fold (range, 1.1–39) [median of 2,249 IU/ml at baseline vs. median 307 IU/ml at
103 follow-up, $P<0.001$ (Figure 1A)]. One of the two remaining residents developed SARS-
104 CoV-2-S-specific antibodies (8 IU/ml) between sampling times. Antibodies waning was
105 documented more frequently ($P<0.001$) in SARS-CoV-2 naïve (29/35) than in
106 recovered (1/10) residents (Figure 1B).

107 **SARS-CoV-2-S-specific T cells**

108 Data on T cell responses were available for 46 participants. Overall, detectable SARS-
109 CoV-2-S IFN- γ T cells (either CD8⁺, CD4⁺ or both) were documented in 82.6 % (38/46)
110 and 73.9% (34/46) of residents at baseline and follow-up, respectively ($P=0.01$). The
111 corresponding figures for SARS-CoV-2-S IFN- γ CD8⁺ T cells were 72% (33/46) and
112 52.1% (24/46). As shown in Figure 2A, 8 of 13 residents testing negative at baseline
113 later acquired detectable responses, albeit at low frequencies (median, 0.08%; range,
114 0.01–0.21%), whereas SARS-CoV-2-S IFN- γ CD8⁺ T cells were no longer detectable at
115 follow-up in 16 out of 33 residents who tested positive at baseline. SARS-CoV-2-S
116 IFN- γ CD4⁺ T cells were detected in 26% (12/46) and 65.2% (30/46) of residents at

117 baseline and follow-up, respectively. Nineteen participants developed CD4⁺ T cell
118 responses between testing time points (median, 0.1%; range, 0.03-1.14%), whereas one
119 out of 12 with detectable responses at baseline had lost this at follow-up (Figure 2B).
120 The likelihood of having detectable SARS-CoV-2 IFN- γ CD8⁺ and CD4⁺ T at follow-up
121 was higher ($P=0.03$ and $P=0.5$) in SARS-CoV-2 recovered (8/10 and 7/10, respectively)
122 than in naïve residents (9/36 and 25/36, respectively). For those with detectable
123 responses at both time points, overall, SARS-CoV-2-S IFN- γ CD8⁺ T cell frequencies
124 decreased significantly ($P=0.001$) over time whereas the opposite ($P=0.01$) was seen for
125 CD4⁺ T cells (Figure 2C). Interestingly, the resident lacking anti-RBD antibodies at
126 follow-up had detectable SARS-CoV-2-S CD4⁺ T cell responses.

127 Supplementary Table 2 shows the combined results for all immunological parameters.
128 No correlation was found between anti-RBD antibody levels and SARS-CoV-2-S IFN- γ
129 CD4⁺ ($\text{Rho}=-0.015$; $P=0.94$) and CD8⁺ ($\text{Rho}=-0.18$; $P=0.87$) T cells.

130 **DISCUSSION**

131 The main findings of the current study are as follows. First, while SARS-CoV-2-RBD
132 antibodies, which correlate strongly with neutralizing antibody titers [5], were
133 detectable in 97.7% (44/45) of nursing home residents by around 6 months after full
134 vaccination with Comirnaty®, their levels declined significantly over time (a median of
135 5-fold); second, RBD-reactive antibody waning was rather frequent (29/35) in SARS-
136 CoV-2 naïve, but uncommon (1/10) in recovered residents, who overall maintained high
137 antibody levels at follow-up. The above observations were not unexpected as they have
138 also been made in other population groups, including younger individuals seemingly
139 with few or no comorbidities [6-8], at comparable timeframes [7,8] after full
140 vaccination with mRNA vaccines; third, a large percentage of residents (34/46; 73.9%)

141 had detectable SARS-CoV-2-S IFN- γ T cells (either CD8⁺, CD4⁺ or both) at follow-up,
142 SARS-CoV-2-S IFN- γ CD4⁺ T cell responses being more frequently documented than
143 their CD8⁺ T cells counterparts. Interestingly, recovered COVID-19 residents were
144 more likely to display both CD8⁺ and CD4⁺ detectable responses at follow-up than
145 naïve ones. Finally, for those with detectable responses at both sampling times, SARS-
146 CoV-2-S IFN- γ CD8⁺ T cell frequencies decreased significantly, whereas the opposite
147 was observed for CD4⁺ T cells. In this regard, collectively, the above data suggested
148 that SARS-CoV-2-S IFN- γ CD4⁺ T cells may develop later than CD8⁺ T cells in nursing
149 home residents.

150 Limitations of the current study are the relatively small sample size and lack of a control
151 group; regarding the latter, most of the 17 controls included in our previous study [2]
152 were unfortunately not available for follow-up sampling. Secondly, neutralization
153 assays were not carried out. In summary, our data revealed that a large percentage of
154 nursing home residents displayed detectable SARS-CoV-2-S-reactive antibodies and T
155 cell responses, respectively, by around 6 months after complete vaccination with
156 Comirnaty® COVID-19 vaccine, although these generally declined over time. Whether
157 these mid-term immune responses suffice to prevent COVID-19 remains to be
158 determined. Our data also suggested that a booster (third) dose, which has been
159 proposed for elderly people [9,10] may be delayed beyond 6 months in fully vaccinated
160 COVID-19 recovered residents.

161 **ACKNOWLEDGMENTS**

162 We are grateful to all personnel who work at nursing home residences affiliated to the
163 Clínico-Malvarrosa Health Department and at Clinic University Hospital, in particular
164 to those at the Microbiology laboratory, for their commitment in the fight against

165 COVID-19. Ignacio Torres holds a Río Hortega Contract (CM20/00090) from the
166 Carlos III Health Institute. Eliseo Albert holds a Juan Rodés Contract (JR20/00011)
167 from the Carlos III Health Institute. Estela Giménez holds a Juan Rodés Contract
168 (JR18/00053) from the Carlos III Health Institute.

169 **FINANCIAL SUPPORT**

170 This work received no public or private funds.

171 **CONFLICTS OF INTEREST**

172 The authors declare no conflicts of interest.

173 **AUTHOR CONTRIBUTIONS**

174 EG, JA, IT, EA, MJA, PA, MJR, DH and BO: Methodology and data validation. PB,
175 MJB, CR: in charge of implementing public health policies to combat SARS-CoV-2
176 epidemic at nursing home residences affiliated to the Clínico-Malvarrosa Health
177 Department. DN: Conceptualization, supervision, writing the original draft. All authors
178 reviewed the original draft.

179 **REFERENCES**

- 180 1. White EM, Yang X, Blackman C, Feifer RA, Gravenstein S, Mor V. Incident SARS-
181 CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home
182 Residents. *N Engl J Med* 2021;385:474-476.
- 183 2. Torres I, Albert E, Giménez E, Alcaraz MJ, Botija P, Amat P, et al. B and T cell
184 immune responses elicited by the Comirnaty COVID-19 vaccine in nursing-home
185 residents. *Clin Microbiol Infect* 2021;S1198-743X(21)00332-3.

- 186 3. Salmerón Ríos S, Mas Romero M, Cortés Zamora EB, Taberero Sahuquillo MT,
187 Romero Rizos L, Sánchez-Jurado PM, et al. Immunogenicity of the BNT162b2 vaccine
188 in frail or disabled nursing home residents: COVID-A study. *J Am Geriatr Soc*
189 2021;69:1441-1447.
- 190 4. Blain H, Tuailon E, Gamon L, Pisoni A, Miot S, Rolland Y, et al. Antibody response
191 after one and two jabs of the BNT162b2 vaccine in nursing home residents: The
192 CONSORT-19 study. *Allergy* 2021 Jul 19. doi: 10.1111/all.15007.
- 193 5. Higgins V, Fabros A, Kulasingam V. Quantitative measurement of anti-SARS-CoV-2
194 antibodies: Analytical and clinical evaluation. *J Clin Microbiol* 2021;59:e03149-20.
- 195 6. Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of
196 antibody response to BNT162b2 vaccine after six months: a longitudinal prospective
197 study. *Lancet Reg Health Eur* 2021 Sep 6:100208.
- 198 7. Tré-Hardy M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, Della Vecchia A,
199 Horeanga A, et al. Six-month interim analysis of ongoing immunogenicity surveillance
200 of the mRNA-1273 vaccine in healthcare workers: A third dose is expected. *J Infect*
201 2021:S0163-4453(21)00433-3.
- 202 8. Dimeglio C, Herin F, Miedougé M, Da-Silva I, Porcheron M, Martin-Blondel G, et
203 al. One year later: SARS-CoV-2 immune response and vaccination of healthcare
204 workers post-infection. *J Infect* 2021;83:381-412.
- 205 9. Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in
206 older people. *Age Ageing* 2021;50:279-283.

207 10. Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al.
208 Considerations in boosting COVID-19 vaccine immune responses. *Lancet*, 2021.
209 DOI:[https://doi.org/10.1016/S0140-6736\(21\)02046-8](https://doi.org/10.1016/S0140-6736(21)02046-8)

210 11. Callaway E. COVID vaccine boosters: the most important questions. *Nature*. 2021
211 Aug;596(7871):178-180.

212 12. Mattiuzzo G, Bentley EM, Hassall M, Routley S, Richardson S, Bernasconi V, et al.
213 Establishment of the WHO International Standard and Reference Panel for anti-SARS-
214 CoV-2 antibody. WHO/BS/2020.2403, December 10, 2020.


215 **FIGURE LEGENDS**

216 **Figure 1.** (A) SARS-CoV-2-S (RBD) plasma antibody (IgG and IgM) levels as
217 measured by Roche Elecsys® Anti-SARS-CoV-2-S immunoassay in nursing home
218 residents with (recovered) or without (naïve) documented prior SARS-CoV-2 infection
219 at baseline (median, 17.5 days) and follow-up (median, 195 days) after complete
220 Comirnaty® COVID-19 vaccination. The limit of detection of the assay is 0.4 IU/ml
221 and its quantification range is between 0.8 and 250 IU/ml. Plasma specimens were
222 further diluted (1/10) for antibody quantitation when appropriate. The assay is calibrated
223 with the first WHO International Standard and Reference Panel for anti-SARS-CoV-2
224 antibody [12]. Bars represent median levels. (B) Individual kinetics of SARS-CoV-2-S
225 (RBD) plasma antibodies in recovered and naïve nursing home residents. *P*-values for
226 comparisons are shown (ns; not significant).

227 **Figure 2.** SARS-CoV-2-S-reactive IFN- γ -producing T cell levels in SARS-CoV-2
228 naïve and or recovered nursing home residents measured at baseline (median, 17.5 days)
229 and follow-up (median, 195 days) after complete Comirnaty® COVID-19 vaccination.
230 Briefly, heparinized whole blood (0.5 ml) was simultaneously stimulated for 6 h with

231 two sets of 15-mer overlapping peptides (11-mer overlap) encompassing the
232 SARS-CoV-2 Spike (S) glycoprotein (S1, 158 peptides and S2, 157 peptides) at a
233 concentration of 1-µg/ml per peptide, in the presence of 1-µg/ml of costimulatory
234 monoclonal antibodies (mAbs) to CD28 and CD49d. Peptide mixes were obtained from
235 JPT peptide Technologies GmbH (Berlin, Germany). Samples mock-stimulated with
236 phosphate-buffered saline (PBS)/dimethyl sulfoxide and costimulatory antibodies were
237 run in parallel. Brefeldin A (10-µg/ml) was added for the last 4-h of incubation. Blood
238 was then lysed (BD FACS lysing solution) and frozen at -80°C until tested. On the day
239 of testing, stimulated blood was thawed at 37°C, washed, permeabilized (BD
240 permeabilizing solution) and stained with a combination of labeled mAbs
241 (anti-IFN-γ-FITC, anti-CD4-PE, anti-CD8-PerCP-Cy5.5, and anti-CD3-APC)
242 for 1-h at room temperature. Appropriate positive (phytohemagglutinin) and isotype
243 controls were used. Cells were then washed, resuspended in 200-µL of 1%
244 paraformaldehyde in PBS, and analyzed within 2-h on an FACSCanto flow cytometer
245 using DIVA v8 software (BD Biosciences Immunocytometry Systems, San Jose, CA).
246 CD3⁺/CD8⁺ or CD3⁺/CD4⁺ events were gated and then analyzed for IFN-γ production.
247 All data were corrected for background IFN-γ production (FITC-labelled isotype control
248 antibody) and expressed as a percentage of total CD8⁺ or CD4⁺ T cells. (A) Individual
249 kinetics for SARS-CoV-2-S-reactive IFN-γ CD8⁺ T cells. (B) Individual kinetics for
250 SARS-CoV-2-S-reactive IFN-γ CD4⁺ T cells. (C) Frequencies of SARS-CoV-2-S-
251 reactive IFN-γ CD8⁺ and CD4⁺ T cells in nursing home residents with detectable
252 responses at both baseline and follow-up. T cells. *P*-values for comparisons are shown
253 (ns; not significant).

A



B

